NCT01919554View on ClinicalTrials.gov

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Allergic Rhinitis Due to House Dust Mite
Interventions
BIOLOGICAL

500 IR house dust mites allergen extract tablet

One sublingual tablet daily during 10 days

BIOLOGICAL

1000 IR house dust mites allergen extract tablet

Two sublingual tablets daily during 10 days

BIOLOGICAL

1500 IR house dust mites allergen extract tablet

Three sublingual tablets daily during 10 days

BIOLOGICAL

Placebo tablet

One, two or three sublingual placebo tablets daily during 10 days matching with the sublingual immunotherapy tablets

Trial Locations (1)

L4W 1N2

Inflamax Research Inc., Mississauga

Sponsors

Lead Sponsor

Stallergenes Greer

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Stallergenes Greer

INDUSTRY